MaRS Peer to Peer Series - The COLD-FX story

of 26 /26
Jacqueline Shan, Ph.D., D.Sc President and Chief Scientific Officer Afexa Life Sciences Inc. (Formally CV Technologies Inc) Edmonton, Canada Presentation to MaRS Discovery, May 5th, 2009

Embed Size (px)

Transcript of MaRS Peer to Peer Series - The COLD-FX story

  1. 1. Jacqueline Shan, Ph.D., D.Sc President and Chief Scientific Officer Afexa Life Sciences Inc. (Formally CV Technologies Inc) Edmonton, Canada Presentation to MaRS Discovery, May 5th, 2009
  2. 2. Chronic diseases such as cardiovascular diseases,obesity and diabetes will account for 70% of alldeath worldwide by 2020-WHO In 2001, chronic diseases contributed 60% of alldeath worldwide and 46% of the total burden ofdiseases Increases in disease incidence lead to overallincreases in the cost of healthcare Our current healthcare system is a diseases-caresystem. 75% was spent on treating chronic diseasesthat are preventable or even reversible by changingdiet and lifestyle 2
  3. 3. Nature: a great source of Medicine Shorter Discovery Phase Mature Pharmaceutical Development Models for advanced preclinical and Clinical phases Better Safety Profile Prevention and Intervention Sustainable and Affordable Canadian and International Regulatory Framework: Canada, US and Asia Safe and Effective Green and environmental friendly3
  4. 4. To transform people's lives to be healthier and happier by focusing on prevention and recoverythrough the use of evidence-based naturally- derived health products. 4
  5. 5. Spin off from U of A in 1992 Direction of innovation: Natural Health Product (NHP)Standardization Technology Immunotherapy forinfectious diseases, Cancer management, MetabolicSyndrome management, Neuropsychologicalmanagement Extensive patent folio, Proprietary TechnologyPlatform- ChemBioPrint Technology Successful commercialization with lead productCOLD-fX since 2003 5
  6. 6. Economic burden of Colds and Flu - $4-6 billion Lack of conventional and effective drugs and vaccines Unnecessary and ineffective physician visits Loss of work days and productivity6
  7. 7. 7
  8. 8. More than a decade of research 10 clinical trials Published in 9 major peer-reviewed medical journals Safe and effective International Olympic Committee (IOC) protocoltesting demonstrated that COLD-FX did not containor induce any banned substances, unlike some coldmedicines Health Canada NPN approval8
  9. 9. 9
  10. 10. 10
  11. 11. COLD-FX Net Sales ($ CDN millions) *Sales includes all Afexa products, year-end September 30 11
  12. 12. COLD-fX #1 selling brand for all cold remedies& natural supplements* * Source: Nielsen Brand Overview, National All Channels total Cold Remedies (includingantihistamines) and Natural supplements for 52 weeks ending December 22, 200712
  13. 13. Today COLD-fX 60s is the #1 selling cold remedy in Canada The COLD-fX brand is essentially tied for first place among allCough/Cold brands with 3 skusBrandBrandRankTotal $ # of SKUsTYLENOL1 $38.0 million 47COLD-fX 2 $37.9 million3ADVIL3 $30.6 million 16NYQUIL/DAYQUIL 4 $18.0 million 16NEO CITRAN 5 $13.7 million 28CONTAC 6$7.9 million 35BENYLIN7$7.6 million 14SUDAFED8$6.9 million 18DIMETAPP 9$6.8 million 13SINUTAB 10$5.8 million 14 13
  14. 14. Pharmacy Post magazines #1 pharmacist recommended natural cold remedy 14
  15. 15. First evidence based and safe NHP for cold and fluprevention and treatment-a better choice overtraditional drugs and added benefit to flu vaccine Consumer acceptance prove Canadians willing toproactively prevent and manage colds and flu Positive social and economic outcome: Prevention, improving quality of life, reducing possible doctor visits and unnecessary prescriptions, reduce work day loss and improve productivity 15
  16. 16. Going forward, the market opportunity isntnecessarily to steal share, but rather to becomplimentary to traditional treatment remedies Expansion of preventative solution options aspotential source for future market growth16
  17. 17. U.S. National Cancer Institute (NCI)- WORLDS TOPCANCER RESEARCH BODY SPONSORS LANDMARKCOLD-FX TRIALThe landmark sponsored trial involving chronic lymphocyteleukemia patients the first time the natural medicine willbe part of a clinical study associated with cancer. 17
  18. 18. Committing to Our Vision Committing to Science and Quality Committing to Discipline, High Integrity and BestBusiness Practice Adapting to Change and Move Fast Thinking Big but One-step at a Time Being an Innovative Trail Blazer and Not AcceptingFailure Valuing Team Work and Respecting and Helping OurTeammates Having a Can-do Attitude and Being Passionateabout Our Cause 18
  19. 19. Afexa products are an environmentally responsible choice for consumers All natural products Scientifically developed andrigorously produced Safe for the human body Devoid of synthetic chemicalsthat degrade the environment19
  20. 20. Increased Public Awareness and Demands >10,000 Retail Establishments $2.5 billion retail sales in NHPs, $3 billion inFunctional foods and growing International Opportunities 20
  21. 21. Could create new emerging preventative,evidence-based NHP/Functional food industryfor disease prevention and health promotion Innovative products and technology could reshape and improve healthcare landscape21
  22. 22. Regulatory uncertainty on pathways and healthclaims Management expertise in commercialization Research & innovation capacity and capability(Funding, validated methods, scale-up facilities) Access to technology and ownership of IPs Under-informed health care professionals andconsumers on diet-health relationship andpotential NHPs contribution to health Global presence and competitiveness 22
  23. 23. Stream-lining and improving regulatory framework forNHPs and functional foods Integrating Evidence-based NHPs and FunctionalFoods into health care and health management Emphasizing and integrating prevention intohealthcare policies Investing and building an integrated innovation andresearch infrastructure including Agi-Food, Health andInnovation Investing and encouraging entrepreneurship andcommercialization 23
  24. 24. Helping streamline regulatory framework and policies Investing and encouraging research and innovation Investing and encouraging commercialization: e.g., clinical research and validation; production scale-up Investing and encouraging training skilled scientific and business professionals Facilitating assess to research and technologies IP policy to allow industry owning IP or the right of IP24
  25. 25. Cross Sector Collaboration Industry Focusing on Accessing and Utilizing the Innovation and Technology Leveraging the Resources, Compliment the Strengths Building a Viable NPH and Functional Food Industry and Research Community Together 25
  26. 26. 26